Segments covered in the global non-small cell lung cancer treatment market report:
The global non-small cell lung cancer treatment market is segmented based on treatment type, marketed brand , distribution channel, and region as follows:
- Treatment Type (Revenue, USD Billion; 2022–2030)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
- Marketed Brand (Revenue, USD Billion; 2022–2030)
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Others
- Distribution Channel (Revenue, USD Billion; 2022–2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region (Revenue, USD Billion; 2022–2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
- North America
Frequently Asked Questions
The current market size of the non-small cell lung cancer (NSCLC) treatment industry is estimated to be US$ 26.2 billion in 2023.
Rising prevalence of NSCLC, increasing demand for targeted therapies, and technological advancements are contributing significantly to the growth of the Non-small Cell Lung Cancer Treatment market.
The key factors hampering the growth of the Non-small Cell Lung Cancer Treatment Market are high cost of treatment and limited access to care in developing countries.
The leading component segment in the Non-small Cell Lung Cancer Treatment Market is targeted therapies.
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Johnson & Johnson, Merck, Novartis, Pfizer, Takeda are the major players operating in the Non-small Cell Lung Cancer Treatment Market.
The non-small cell lung cancer treatment market is expected to grow at a CAGR of 8.9% and reach a market size of US$ 47.5 billion by 2030.